Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INV-1120 |
Synonyms | |
Therapy Description |
INV-1120 is an antagonist of the prostaglandin E2 receptor subtype 4 (EP4), and inhibits binding of the prostaglandin E2 to EP4, potentially leading to altered anti-tumor immune response and inhibition of cell proliferation (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INV-1120 | INV1120|INV 1120 | INV-1120 is an antagonist of the prostaglandin E2 receptor subtype 4 (EP4), and inhibits binding of the prostaglandin E2 to EP4, potentially leading to altered anti-tumor immune response and inhibition of cell proliferation (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04443088 | Phase I | INV-1120 | A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors | Recruiting | USA | 0 |